Novel radionuclides for use in Nuclear Medicine in Europe: where do we stand and where do we go?
Abstract Background In order to support the ongoing research across Europe to facilitate access to novel radionuclides, the PRISMAP consortium (European medical radionuclides programme) was established to offer the broadest catalog of non-conventional radionuclides for medical and translational rese...
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SpringerOpen
2023-10-01
|
| Series: | EJNMMI Radiopharmacy and Chemistry |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s41181-023-00211-5 |
| _version_ | 1797555633195581440 |
|---|---|
| author | Maija Radzina Laura Saule Edgars Mamis Ulli Koester Thomas Elias Cocolios Elina Pajuste Marika Kalnina Kristaps Palskis Zoe Sawitzki Zeynep Talip Mikael Jensen Charlotte Duchemin Kirsten Leufgen Thierry Stora |
| author_facet | Maija Radzina Laura Saule Edgars Mamis Ulli Koester Thomas Elias Cocolios Elina Pajuste Marika Kalnina Kristaps Palskis Zoe Sawitzki Zeynep Talip Mikael Jensen Charlotte Duchemin Kirsten Leufgen Thierry Stora |
| author_sort | Maija Radzina |
| collection | DOAJ |
| description | Abstract Background In order to support the ongoing research across Europe to facilitate access to novel radionuclides, the PRISMAP consortium (European medical radionuclides programme) was established to offer the broadest catalog of non-conventional radionuclides for medical and translational research. The aim of this article is to introduce readers with current status of novel radionuclides in Europe. Main body A consortium questionnaire was disseminated through the PRISMAP consortium and user community, professional associations and preclinical/clinical end users in Europe and the current status of clinical end-users in nuclear medicine were identified. A total of 40 preclinical/clinical users institutions took part in the survey. Clinical end users currently use the following radionuclides in their studies: 177Lu, 68 Ga, 111In, 90Y, other alpha emitters, 225Ac, 64Cu and Terbium isotopes. Radionuclides that would be of interest for users within the next 2–5 years are 64Cu, Terbium radionuclide “family” and alpha emitters, such as 225Ac. Conclusions Thanks to a questionnaire distributed by the PRISMAP consortium, the current status and needs of clinical end-users in nuclear medicine were identified. |
| first_indexed | 2024-03-10T16:50:16Z |
| format | Article |
| id | doaj.art-ea5d731c4aaa4b13b7dff743bd86eb1d |
| institution | Directory Open Access Journal |
| issn | 2365-421X |
| language | English |
| last_indexed | 2024-03-10T16:50:16Z |
| publishDate | 2023-10-01 |
| publisher | SpringerOpen |
| record_format | Article |
| series | EJNMMI Radiopharmacy and Chemistry |
| spelling | doaj.art-ea5d731c4aaa4b13b7dff743bd86eb1d2023-11-20T11:21:10ZengSpringerOpenEJNMMI Radiopharmacy and Chemistry2365-421X2023-10-018111610.1186/s41181-023-00211-5Novel radionuclides for use in Nuclear Medicine in Europe: where do we stand and where do we go?Maija Radzina0Laura Saule1Edgars Mamis2Ulli Koester3Thomas Elias Cocolios4Elina Pajuste5Marika Kalnina6Kristaps Palskis7Zoe Sawitzki8Zeynep Talip9Mikael Jensen10Charlotte Duchemin11Kirsten Leufgen12Thierry Stora13University of LatviaUniversity of LatviaUniversity of LatviaInstitut Laue-LangevinKU LeuvenUniversity of LatviaUniversity of LatviaCERNKU LeuvenPaul Scherrer Institute (PSI)Technical University of DenmarkCERNSCIPROM SarlCERNAbstract Background In order to support the ongoing research across Europe to facilitate access to novel radionuclides, the PRISMAP consortium (European medical radionuclides programme) was established to offer the broadest catalog of non-conventional radionuclides for medical and translational research. The aim of this article is to introduce readers with current status of novel radionuclides in Europe. Main body A consortium questionnaire was disseminated through the PRISMAP consortium and user community, professional associations and preclinical/clinical end users in Europe and the current status of clinical end-users in nuclear medicine were identified. A total of 40 preclinical/clinical users institutions took part in the survey. Clinical end users currently use the following radionuclides in their studies: 177Lu, 68 Ga, 111In, 90Y, other alpha emitters, 225Ac, 64Cu and Terbium isotopes. Radionuclides that would be of interest for users within the next 2–5 years are 64Cu, Terbium radionuclide “family” and alpha emitters, such as 225Ac. Conclusions Thanks to a questionnaire distributed by the PRISMAP consortium, the current status and needs of clinical end-users in nuclear medicine were identified.https://doi.org/10.1186/s41181-023-00211-5RadionuclidesDiagnosticTherapyPET/CTPRISMAP programme |
| spellingShingle | Maija Radzina Laura Saule Edgars Mamis Ulli Koester Thomas Elias Cocolios Elina Pajuste Marika Kalnina Kristaps Palskis Zoe Sawitzki Zeynep Talip Mikael Jensen Charlotte Duchemin Kirsten Leufgen Thierry Stora Novel radionuclides for use in Nuclear Medicine in Europe: where do we stand and where do we go? EJNMMI Radiopharmacy and Chemistry Radionuclides Diagnostic Therapy PET/CT PRISMAP programme |
| title | Novel radionuclides for use in Nuclear Medicine in Europe: where do we stand and where do we go? |
| title_full | Novel radionuclides for use in Nuclear Medicine in Europe: where do we stand and where do we go? |
| title_fullStr | Novel radionuclides for use in Nuclear Medicine in Europe: where do we stand and where do we go? |
| title_full_unstemmed | Novel radionuclides for use in Nuclear Medicine in Europe: where do we stand and where do we go? |
| title_short | Novel radionuclides for use in Nuclear Medicine in Europe: where do we stand and where do we go? |
| title_sort | novel radionuclides for use in nuclear medicine in europe where do we stand and where do we go |
| topic | Radionuclides Diagnostic Therapy PET/CT PRISMAP programme |
| url | https://doi.org/10.1186/s41181-023-00211-5 |
| work_keys_str_mv | AT maijaradzina novelradionuclidesforuseinnuclearmedicineineuropewheredowestandandwheredowego AT laurasaule novelradionuclidesforuseinnuclearmedicineineuropewheredowestandandwheredowego AT edgarsmamis novelradionuclidesforuseinnuclearmedicineineuropewheredowestandandwheredowego AT ullikoester novelradionuclidesforuseinnuclearmedicineineuropewheredowestandandwheredowego AT thomaseliascocolios novelradionuclidesforuseinnuclearmedicineineuropewheredowestandandwheredowego AT elinapajuste novelradionuclidesforuseinnuclearmedicineineuropewheredowestandandwheredowego AT marikakalnina novelradionuclidesforuseinnuclearmedicineineuropewheredowestandandwheredowego AT kristapspalskis novelradionuclidesforuseinnuclearmedicineineuropewheredowestandandwheredowego AT zoesawitzki novelradionuclidesforuseinnuclearmedicineineuropewheredowestandandwheredowego AT zeyneptalip novelradionuclidesforuseinnuclearmedicineineuropewheredowestandandwheredowego AT mikaeljensen novelradionuclidesforuseinnuclearmedicineineuropewheredowestandandwheredowego AT charlotteduchemin novelradionuclidesforuseinnuclearmedicineineuropewheredowestandandwheredowego AT kirstenleufgen novelradionuclidesforuseinnuclearmedicineineuropewheredowestandandwheredowego AT thierrystora novelradionuclidesforuseinnuclearmedicineineuropewheredowestandandwheredowego |